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Commentary
Differences in perspective on basic research 
studies versus large-scale, guideline-compliant 
studies evaluating the potential develop  mental/ 
reproductive effects of bisphenol A (BPA) 
reported by Myers et al. (2009) reflect dis-
agreement in and ignorance of the roles and 
strengths and weaknesses of these study types. 
This controversy affects BPA safety assessment, 
which has become a major public policy issue. 
In this article I review charac  teris  tics and uses 
of basic/exploratory research versus regulatory 
guideline-compliant studies, using BPA as a 
case study.
Background
Basic/exploratory research in toxicology is 
conducted to identify unknown potential 
hazards, elucidate the mode/mechanism of 
action for known toxicants, or explore novel 
end points for possible subsequent formal 
validation. These studies commonly employ 
routes of administration and/or doses that 
are not relevant for humans; include few dose 
groups and few animals per group, and/or 
nonvalidated end points; are not tracked to 
adverse outcomes; and are typically creative, 
short term, relatively inexpensive, and funded 
by universities, government grants, and non-
governmental organizations (NGOs). These 
basic research studies play significant roles 
but are limited in assessing potential risks to 
human health. To assess risks, governmental 
agencies rely on guideline-compliant studies 
using appropriate exposures (routes, doses, 
durations), validated end points linked to 
adverse outcomes, and appropriate group sizes 
and numbers. Exploratory research and risk 
assessment studies are interactive and iterative 
(National Research Council 2000).
Risk-relevant studies are performed under 
regulatory testing guideline (TG) protocols 
and Good Laboratory Practices (GLPs). The 
Food and Drug Administration (FDA 1978) 
established standards for design, conduct, and 
reporting of non  clinical laboratory studies in 
support of applications for FDA marketing 
permits. The U.S. Environmental Protection 
Agency (EPA) prescribed GLP standards for 
studies on health and environmental effects 
and chemical fate testing under the Federal 
Insecticide, Fungicide and Rodenticide Act 
(FIFRA; U.S. EPA 1983) and under the Toxic 
Substances Control Act (TSCA; U.S. EPA 
1989). The Organisation for Economic 
Co-operation and Development (OECD) has 
also established GLPs (OECD 1998). The 
U.S. EPA may consider data not developed 
in accordance with these provisions “insuf-
ficient to evaluate the health effects, envi-
ronmental effects, and fate of the chemical.” 
(U.S. EPA 1985).
Guideline-compliant studies evaluate 
potential hazard and risk of substances and are 
performed following/exceeding governmental 
TGs and GLPs. Guideline-compliant multi-
generational reproductive toxicity studies, 
with large numbers of animals per group per 
generation, are very expensive and typically 
funded by manufacturers, consortia of manu-
facturers, and/or governments. These studies 
are necessary for hazard evaluation and/or risk 
assessment because of their statistical power to 
detect reproducible effects linked to adverse 
outcomes; relevant exposure routes, doses, and 
animal models; and dose–response assessment. 
GLPs require complete, permanent documen-
tation of staff; valid study design; standard 
operating procedures (SOPs); training, perfor-
mance, formulation, and statistical analyses; 
and retention of summary/individual data, so 
there is confidence in the study design, per-
formance, and results, and anyone can sub-
sequently fully reconstruct the study.
Harmonization of TGs by the OECD 
[United States (U.S. EPA), Japan, and 
Europe] for industrial chemicals, and by the 
International Conference on Harmonization 
(European Commission, Japanese Ministry, 
U.S. FDA, and pharmaceutical manu-
facturers) for pharmaceuticals, ensures guide-
lines are globally consistent and acceptable. 
Development and revision of governmental 
regulatory guidelines involve experts from 
govern  ment, academia, and industry evaluat-
ing the strengths and weaknesses of the current 
and proposed TGs and end points. For the 
revised two-generation study TGs, new vali-
dated end points include ano  genital distance 
(AGD), retained nipples/areolae, acquisi  tion of 
puberty, estrous cyclicity, andrology, and ovar-
ian primordial follicle counts. Proposed guide-
lines (and/or new end points) are published for 
comment (e.g., U.S. EPA 1996). After com-
ments and revisions, the final guideline is pub-
lished [U.S. EPA TSCA new two-genera  tion 
guideline (U.S. EPA 1997); U.S. EPA Office 
of Prevention, Pesticides, and Toxic Substances 
(OPPTS; including TSCA and FIFRA) version 
1998; and the new OECD version (OECD 
2001)]. TGs evolve over time, and appropriate 
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changes are incorporated as described above. 
If/when researchers identify new end points 
for inclusion, there is a defined process to   
follow. Virtually all new validated end points 
in current guidelines originated in exploratory 
research.
When a government guideline is developed 
for a “new” study type, such as the rat ovariec-
tomized uterotrophic and castrate Hershberger 
assays for endocrine disruptors, a laboratory 
evaluates the protocol’s variables, and govern-
mental, industrial, and contract testing labo-
ratories run the protocol with known (and 
coded) chemicals. A background review 
document with laboratory results and a draft 
guideline are published. The process involves 
scientists, testing laboratories, govern  mental 
oversight, and peer review before the guideline 
and/or end point(s) is officially acceptable. 
Although TGs are comprehensive and provide 
a robust baseline standard, one can also add 
evaluations to enhance the ability of the guide-
line to detect adverse effects.
Guideline studies are required for govern-
mental risk assessment and critical for risk 
evaluations by other agencies, such as the 
National Toxicology Program (NTP 2008), 
the Center for the Evaluation of Risks to 
Human Reproduction (CERHR 2008), and 
the European Food Safety Authority (EFSA 
2006). Guideline studies can inform fur-
ther exploratory research and are universally 
considered robust, reliable, and essential to 
confirm, refute, and/or expand exploratory 
studies. When appropriate, non  validated end 
points can be used in formal risk assessments 
as “points of departure,” but only when the 
end point is known to relate directly to an 
adverse outcome; for example, fetal testicu  lar 
testosterone content was used as the point of 
departure for a U.S. EPA phthalate risk assess-
ment because the direct adverse consequences 
from low fetal testosterone were known.
BPA is a high-production-volume chemical.   
Ubiquitous human exposure to very low BPA 
doses occurs primarily through consumption 
of food that comes in contact with materi-
als containing BPA, such as polycarbon-
ate plastics and epoxy resins (manufactured 
from BPA) used in plastic bottles, and food/ 
beverage container coatings (EFSA 2006). 
There is considerable debate on whether low 
oral BPA doses cause reproductive/develop-
mental effects in animals. Guideline-compliant 
BPA studies have shown effects only at high 
doses, which also caused parental systemic tox-
icity, but have not reproduced the low-dose 
effects reported in exploratory BPA studies.
Myers et al. (2009) criticized GLP-
compliant studies for serious conceptual 
and methodologic flaws, failure to address   
replication, and using methods not sensitive 
or “state of the art” and opined that these 
studies cannot detect effects of low-dose BPA. 
They specifically criticized our BPA [and 
17β-estradiol (E2)] dietary studies (Tyl et al. 
2002, 2008a, 2008b, 2008c).
Guideline-Compliant 
BPA Studies
Our three-generation reproductive toxicity 
study of dietary BPA in CD(SD) rats (under 
OPPTS guideline 870.03800; U.S. EPA 1998) 
included six BPA dose groups (30/sex/group/
generation) at 0.015–7,500 ppm (~ 0.001–
500 mg/kg/day) (Tyl et al. 2002). We found 
no non  monotonic dose–response patterns 
or effects on any parameters in the low-dose 
region (1 µg/kg/day to 5 mg/kg/day). We 
reported reduced adult body and organ weights 
at ≥ 50 mg/kg/day and renal and hepatic histo-
pathology at 500 mg/kg/day. Reproductive/
developmental toxicity was present only at 
500 mg/kg/day in the presence of overt adult 
systemic toxicity. At doses < 500 mg/kg/day, 
we found no BPA effects on prostate weights 
(lobe or whole gland), acquisition of puberty, 
or other reproductive organ weights or histo-
pathology in adult offspring. The systemic no 
observable adverse effect level (NOAEL) was 
5 mg/kg/day, and the reproductive/develop-
mental NOAEL was 50 mg/kg/day. BPA was 
not considered a rat selective reproductive/
developmental toxicant.
Ema et al. (2001), funded by the Japanese 
Ministry of Health and Welfare, published 
a two-generation BPA rat study, with daily 
gavage dosages of 0 and 0.2–200 µg/kg/day 
under U.S. EPA GLPs and OPPTS TG (U.S. 
EPA 1998), adding endocrine-sensitive and 
neuro  behavioral end points. They found no 
significant, compound-related effects in any 
parameter at any dose, consistent with our 
conclusions.
Myers et al. (2009) criticized our rat study 
for the absence of a positive control, although 
we reported successful use of 2.5 ppm dietary 
E2 (~ 180–200 µg/kg/day) in another dietary 
multi  generational study using the same rat 
source (Tyl et al. 2006). Biegel et al. (1998), 
using a 90-day plus one-generation study 
design, evaluated dietary E2 in CD(SD) 
rats; determined that dietary concentrations 
of 10 and 50 ppm were incompatible with 
pregnancy or offspring, and found the same 
effects at 2.5 ppm as we did. A “positive con-
trol” group is neither required nor routinely 
employed in guideline-compliant studies, 
because the study design and end points are 
validated (i.e., known to result in adverse con-
sequences from an appropriate chemical by 
appropriate routes and doses). Neurotoxicity 
guideline protocols require annual evaluation 
of the test system with positive controls.
Because rats were cited as insensitive (or less 
sensitive than mice) to estrogens, mouse BPA 
reproductive toxicity studies were requested by 
European regulatory agencies. Our laboratory 
performed one- and two-genera  tion repro-
ductive toxicity studies of dietary E2 in CD-1 
mice (Tyl et al. 2008a, 2008b) under OECD 
guidelines and GLPs, to establish appropriate 
end points and effects at low to high doses 
of an endogenous estrogen and to deter-
mine the appropriate dietary E2 positive con-
trol concentration/dose for the subsequent 
dietary BPA study in CD-1 mice. We evalu-
ated dietary E2 concentrations from 0.001 to 
50 ppm (~ 0.2 µg/kg/day to ~ 8 mg/kg/day). 
Doses ≥ 400 µg/kg/day (≥ 2.5 ppm) resulted 
in normal F0 mating behavior but no pregnan-
cies or F1 offspring (Tyl et al. 2008a). Doses 
of ~ 0.2–80 µg/kg/day E2 (0.001–0.5 ppm) 
resulted in appropriate reproductive functions 
over one and two adult/offspring generations 
(Tyl et al. 2008a, 2008b), with anticipated 
dose-related effects on acquisition of puberty 
[accelerated vaginal patency (VP), delayed 
preputial separation] and AGD (shortened in 
males); these doses also affected weights of ova-
ries, uterus, cervix, and vagina, but not prostate 
and non  monotonic dose–response curves for 
any parameter. The most complete spectrum 
of E2-dependent effects occurred at 0.5 ppm in 
the E2 two-generation study (Tyl et al. 2008b), 
such that E2 concentration (~ 80–120 µg/kg/
day) was the positive control for the mouse 
dietary BPA study.
The mouse study (Tyl et al. 2008c), under 
OECD GLPs and guidelines, involved two 
vehicle control groups (0 ppm), six dietary 
BPA dose groups (0.018–3,500 ppm; 
0.003–600 mg/kg/day), and one posi-
tive control group (E2), with 28 mice/sex/
group/generation over two parental and off-
spring generations. One additional post  wean 
F1 male/litter was retained through adult 
necropsy and histo  pathology. E2 results con-
firmed sensitivity of CD-1 mice to estrogen. 
We found no BPA-related effects on mating, 
fertility, or gesta  tional indices or on ovarian 
primordial follicle counts, estrous cyclicity, 
precoital interval, neonatal offspring AGD, 
sex ratios, survival, andrology, reproductive 
organ weights, or histopathology (including 
testes and prostate). Adult systemic effects at 
300 ppm (~ 50 mg/kg/day) included only 
liver histo  pathology; at 3,500 ppm (~ 600 mg/
kg/day), there were reduced body weights, 
increased renal and liver weights, and histo-
pathology in adult males, and transient effects 
on weanling body and organ weights, but no 
adverse effects on adult reproductive struc-
tures or functions. These transient effects were 
considered secon  dary to systemic toxicity. At 
lower doses (0.018–30 ppm; ~ 0.003–5 mg/
kg/day), there were no treatment-related 
effects or non  monotonic dose–response curves 
for any parameter at any dose. The systemic 
NOAEL was 30 ppm BPA (~ 5 mg/kg/day), 
and the reproductive/developmental NOAEL 
was 300 ppm (~ 50 mg/kg/day). BPA was Tyl
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not considered a selective mouse reproductive 
or develop  mental toxicant (Tyl et al. 2008c). 
We identified the same BPA systemic and 
reproductive/developmental NOAELs (and 
sensitivity comparable to similar dietary E2 
intakes) in rats and mice, with no BPA effects 
on the prostate weight or histo  pathology. 
Strain differences in response to estrogens 
in rats (and mice) vary across tissues, so no 
strain can be considered more sensitive than 
another (Howdeshell et al. 2008). E2 activities 
via estrogen receptor-α in the reproductive 
tract did not display major strain differences in 
OECD multi  laboratory rat uterotrophic assay 
validation studies; oral BPA was only a weak 
partial agonist at 400–600 mg/kg/day (Kanno 
et al. 2003).
Pharmacokinetics of BPA
The lack of low-dose effects in oral studies 
is consistent with BPA pharmacokinetics. 
Absorption, distribution, metabolism, and 
elimination (ADME) and any subsequent BPA 
toxicity depend on route of adminis  tration. 
Oral BPA at low (or high) doses is almost 
completely (> 95%) mono  glucuronidated 
by the intestine and/or liver before it enters 
general circulation (Inoue et al. 2001, 2003; 
Pottenger et al. 2000). BPA mono  glucuronide 
(BPA-G) is inactive as an estrogen (Matthews 
et al. 2001; Snyder et al. 2000) and is rap-
idly and almost completely excreted by urine 
and feces in rats (Pottenger et al. 2000) and 
by urine in humans (Dekant and Völkel 
2008; Völkel et al. 2002), with a half-life of 
approximately 4 hr. Although neonatal rats 
and human infants have less glucuronida-
tion enzymes than adults, Domoradzki et al. 
(2003) reported that ≥ 99% of oral 1 mg/kg 
BPA (333- to 1,000-fold higher than human 
peri  natal or adult exposures) in neonatal rats 
was glucuronidated. Calafat et al. (2008) 
confirmed infant BPA metabolism, reporting 
that > 90% BPA in urine from premature 
babies was present as BPA-G. There is much 
higher (and longer) bioavailability of parent 
BPA from non-oral routes of administration 
(Pottenger et al. 2000).
Exploratory Research BPA 
Studies
Exploratory research studies evaluate early, 
molecular, nonvalidated end points but rarely 
follow these initial responses to long-term 
adverse consequences. If the study is well con-
ducted and reproducible and the interpreta-
tion is clear, it can be used to support risk 
assessment. vom Saal’s laboratory (Nagel et al. 
1997) reported enlarged prostates in F1 adult 
CF-1 mouse offspring (six or seven males per 
group) from in utero exposure on gestational 
days (GDs) 11–17 to oral BPA at 2 and 20 µg/
kg/day. These effects on offspring prostate 
weights (no histopathology was performed) 
triggered robust evaluations by Cagen et al. 
(1999) and Ashby et al. (1999), who could not 
replicate Nagel et al.’s prostate findings. The 
studies by Cagen et al. and Ashby et al. were 
criticized for no response to 0.2 µg/kg body 
weight/day diethylstilbestrol (DES) as a “posi-
tive control,” which was recommended to the 
authors by vom Saal; however, oral, low-dose 
DES prostate effects reported by vom Saal 
et al. (1997) have never been replicated. Other 
small mouse studies reported low-dose BPA 
effects on fetal prostate morphometry (Timms 
et al. 2005), acceleration of puberty (not on 
VP but timing of first estrus relative to VP; 
Howdeshell et al. 1999), altered mammary 
gland development (non-oral BPA exposure; 
Markey et al. 2005; Munoz-de-Toro et al. 
2005), and altered mouse behavior (oral BPA; 
Ryan and Vandenbergh 2006). These findings, 
not replicated by robust studies in CF-1 mice 
(Cagen et al. 1999) or guideline-compliant 
studies in CD-1 mice (Tyl et al. 2008c), likely 
prompted the CERHR (2007) to indicate 
“some concern” for BPA’s neuro  behavioral 
effects and “mini  mal concern” for acceler-
ated puberty and prostate weights. The NTP 
prepared its own BPA report (NTP 2008), 
expressing “minimal concern” for effects on 
mammary gland develop  ment and acceler-
ated puberty, and “some concern” for neuro-
behavioral and prostate gland effects.
Responses to Specific Criticisms 
by Myers et al. (2009) 
Myers et al. (2009) criticized the GLP-
compliant studies for serious conceptual and 
methodologic flaws, failure to replicate, and 
methods not sensitive or “state of the art.” They 
argued that industry-sponsored GLP studies 
cannot detect low-dose effects and attacked the 
BPA studies in CD(SD) rats (Tyl et al. 2002) 
because the study used an insensitive species 
and strain [although the NTP conducted 
low-dose, multi  generation reproduction stud-
ies with ethinyl estradiol (EE) and genistein 
in the SD rat and detected estrogenic effects 
(Latendresse et al. 2009)] and in mice (Tyl 
et al. 2008c) as “so flawed as to be useless” 
(Myers et al. 2009). Their specific criticisms 
and my responses are as follows:
Claim 1. Myers et al. (2009) claimed that 
the positive control group used a very high E2 
dosage (0.5 ppm in diet at ~ 0.080 mg/kg/day) 
in contrast to the mouse literature for E2 (e.g., 
Richter et al. 2007; vom Saal et al. 1997). 
They noted that the EFSA report (EFSA 2006) 
failed to acknowledge that only a very high 
positive control dose was sufficient to elicit 
effects, and therefore the studies by Tyl and 
colleagues were insensitive to any estrogen and 
thus inappropriate for use in a study to exam-
ine low-dose estrogenic effects.
Tyl response. The dietary positive con-
trol (0.5 ppm E2) was selected based on 
one-genera  tion (Tyl et al. 2008a) and two-
genera  tion (Tyl et al. 2008b) CD-1 mouse 
studies using E2 doses of 0.001–50 ppm 
(8 mg/kg/day), with the most complete spec-
trum of effects seen at 0.5 ppm [estrogenic 
effects were observed at 0.05 ppm (increased 
weanling uterine weight) with a NOAEL of 
~ 1 µg/kg/day]. Because E2 was dietary (ani-
mals were fed ad libitum, with ADME occur-
ring as they fed), it took higher feed doses 
versus gavage or other routes to achieve the 
same test chemical response. Because almost 
all human BPA exposure is oral (during epi-
sodic eating/drinking), dosed feed is the most 
relevant exposure route.
No studies mentioned by Myers et al. 
(2009) investigated E2 after oral administra-
tion: Gupta (2000), Timms et al. (2005), 
and vom Saal et al. (1997) used DES; Putz 
et al. (2001a, 2001b) used oral EE; Timms 
et al. (2005) used estradiol benzoate by sub-
cutaneous injection in rats, and Leranth et al. 
(2008) used it by subcutaneous capsules in 
primates; vom Saal et al. (1997) used sub-
cutaneously implanted Silastic E2 capsules; 
and Richter et al. (2007) used E2 (and BPA) 
in cell culture. We rejected EE (synthetic and 
greater oral bioavailability) and DES (mul-
tiple modes of action, no reproducible data 
that it is orally active at low doses) as positive 
controls.
In Table 9 of our paper (Tyl et al. 2008a), 
we summarized key findings in rats and 
mice at the highest dietary concentrations 
producing viable offspring (2.5 ppm in rats; 
0.5 ppm in mice), at doses of similar order 
of magnitude: mice, ~ 0.08–0.12 mg/kg/day; 
rats, ~ 0.17–0.2 mg/kg/day. Although there 
are differences in some end points, effects of 
exogenous estrogen in rats and mice are simi-
lar at similar doses. The concerns about our 
positive control and dietary concentration are 
unfounded.
Claim 2. Myers et al. (2009) claimed that 
the “large” prostate weights suggest poor dis-
section technique, and that use of dissection, 
weight, and histopathology of the seminal 
vesi  cles plus coagulating glands (SVCG) 
together was “inappropriate.”
Response. Prostate weights (lobe or whole 
gland) in all mammals evaluated to date have 
increased with age as males mature sexually 
(Sinowatz et al. 1996, for mice), as observed 
in our CD-1 mice. Mean control mouse pros-
tate weights by lobe and age in our studies are 
presented in Table 1. Table 2 shows mean 
mouse whole-prostate weights of mice of vari-
ous ages reported by others.
My laboratory has extensive experience 
in weighing rat and mouse prostate glands 
at various ages. In the Hershberger inter-
laboratory validation study, my laboratory had 
some of the most precise prostate weight data 
and robust treatment-related effects of the Basic research versus guideline studies on BPA
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17 participating laboratories (according to one 
senior OECD/U.S. EPA reviewer; personal 
communication). We performed power cal-
culations on our rat and mouse prostate data 
versus data of Nagel et al. (1997). Because 
of larger sample sizes and smaller coefficients 
of variation, our data have greater power 
to detect small effects than the Nagel data 
(unpublished data). Examination of paraffin 
block faces and slides of the rat and mouse 
prostates in the our studies (Tyl et al. 2002, 
2008c) indicated no evidence of extraneous 
tissue/fat or excessive inflammation.
vom Saal’s CF-1 offspring mice are rou-
tinely group housed by sex for several months 
beginning at weaning, and then singly housed 
for 1 month before necropsy. It is highly 
unlikely that 1 month of single housing com-
pensated for months of group housing and 
its effect on male mouse sexual development; 
the dominant cage male develops large andro-
gen-dependent accessory sex organs (ASOs), 
and subservient cage males have smaller ASOs 
(Bartos and Brain 1993). vom Saal’s CF-1 
mice did not exhibit increased prostate weights 
with age, likely because of his post  wean caging 
regimen. Adult control prostate weights in our 
reproductive toxicity studies with E2 (Tyl et al. 
2008a, 2008b) and BPA (Tyl et al. 2008c) 
(Table 1) are well within the weight range 
of other published studies (Table 2), and, as 
expected, our mouse prostate weights increased 
with increasing age.
We dissected, weighed, and examined 
the SVCG together to prevent tissue damage 
from necropsy separation of these intimately 
associated organs for histopathology, espe-
cially in mice.
Claim 3. Myers et al. (2009) and vom Saal 
(at an FDA hearing on BPA safety assessment 
held 16 September 2008 in Washington, DC) 
stated that our animals must have had high 
incidence and severity of prostatitis to account 
for increased prostate weights.
Response. For male mice exposed to E2 
(0, 0.001, 0.005, 0.05, 0.15, and 0.5 ppm), 
histo  pathologic prostate examina  tion by an 
independent pathologist indicated incidences 
of chronic inflammation (plus mono  nuclear 
cell infiltration): for F0 males, 0.0%, 16.7%, 
0.0%, 8.3%, 9.1%, and 0.7%, respectively 
(n = 11–25/group); and for F1 males, 4.0%, 
9.1%, 9.1%, 0.0%, 15.4%, and 0.0% 
(n = 10–25/group) (Tyl et al. 2008b). For the 
mouse BPA study (Tyl et al. 2008c), F0 male 
incidences were 6.7%, 2.2% (vehicle con-
trols), 5.6%, 0.0%, 0.0%, 5.0%, 0.0%, 0.0% 
(BPA low to high doses: 0.018, 0.18, 1.8, 30, 
300, and 3,500 ppm BPA, respectively), and 
0.0% (positive control group; 0.5 ppm E2), 
n = 45–10/group; for F1 males, 3.6% and 
0.0% (vehicle control), 0.0%, 4.2%, 10.0%, 
0.0%, 0.0%, 7.7% (BPA low to high doses), 
and 3.3% (positive control), n = 20–56/group. 
Histopathologic charac  teristics of spontaneous 
prostate lesions in CD-1 mice (Chandra and 
Frith 1992; Karbe 1987; Sugimura et al. 1994; 
Waymouth et al. 1983) include the following:
•	Various	degrees	of	inflammatory	cell	infil-
tration in interstitium
•	Neutrophilic	infiltration	and	cellular	
debris accumulation in acini
•	Minimal	reactive	epithelial	hyperplasia	in	
involved acini (Suwa et al. 2002).
Our incidences in CD-1 mice match low inci-
dences of prostatic inflammation (~ 4–5%) in 
many mouse strains, with no treatment- or 
dose-related changes in incidence or severity.
In our BPA and E2 studies (Tyl et al 2002, 
2008a, 2008b, 2008c), experienced prosectors 
(initially trained by veterinary pathologists) 
dissected reproductive tract organs, includ-
ing prostates for adult and weanling males. 
Technicians were blind for doses (i.e., doses 
designated by Rx number and color code) to 
preclude inadvertent bias during all evalua-
tions. Necropsy order was randomized such 
that prosectors dissected animals from all 
groups on all days, when possible.
Claim 4. Myers et al. (2009) claimed that 
the use of Purina Certified Ground Rodent 
Chow No. 5002 was inappropriate because 
Thigpen et al. (2003) had reported that this 
diet was high in phyto  estrogens and interfered 
with exogenous estrogen activity.
Response. Most exploratory research 
studies, including those of vom Saal and col-
leagues, do not report phyto  estrogen content 
of their diets, so it is difficult to compare diets 
used across laboratories. In our studies, mean 
phytoestrogen content of Purina 5002 feed 
batches was 192 ppm genistein, 177 ppm 
daidzein, and 45 ppm glycitein for mice 
(Tyl et al. 2008c), and 128 ppm genistein, 
131 ppm daidzein, and 50 ppm glycitein for 
rats (Tyl et al. 2002). These levels were rela-
tively consistent across batches within studies 
and across time.
Thigpen et al. (2003) investigated acquisi-
tion of VP in CD-1 mice with various diets 
of low to high phytoestrogen content [spe-
cifically daidzein and genistein (D&G)] and 
concluded that higher dietary phyto  estrogens 
accelerated VP.
Our mouse data indicated control F1 
mean ages at VP were 27.0 (Tyl et al. 2008b) 
and 29.4 (Tyl et al. 2008a) days, with no 
phyto  estrogen effect, because Thigpen et al. 
(2003) reported the following percentages of 
females acquiring VP at 22–30 days of age: 
for low D&G diets (0–20 µg/g), 3.6–86.6%; 
for midrange D&G diets (101–210 µg/g), 
23.8–87.7%; and for high D&G diets   
(270–370 µg/g), 37.5–96.0%. Sensitivity of 
VP to exogenous estrogen was demon  strated 
in our E2 mouse studies, because F1 VP age 
was significantly accelerated to 21.3 days by 
0.5 ppm (Tyl et al. 2008a), to 21.0 days by 
0.15 ppm, and to 20.7 days by 0.5 ppm (Tyl 
et al. 2008b). In our mouse BPA study (Tyl 
et al. 2008c), F1 VP was accelerated to 20.6 
days in the 0.5-ppm E2 positive control group, 
compared with 25.5 days in controls. Our feed 
did not mask endocrine-sensitive responses 
Table 1. CD-1 (Swiss) mouse control male prostate weights (mean ± SD).
Terminal body 
weight (g)
Mean absolute prostate weight (mg)
Reference Age (weeks) Whole prostate Ventral lobe Dorsolateral lobe
Tyl et al. 2008aa 12–13 (F0) 41.19 ± 1.08 43.2 ± 4.7 ND ND
Tyl et al. 2008bb 19 (F0) 36.66 ± 0.77 82.0 ± 6.0 39.0 ± 4.0 42.0 ± 4.0
16–19 (F1) 37.37 ± 0.71 58.0 ± 3.0 25.0 ± 2.0 34.0 ± 2.0
18 (F1 retained) 38.89 ± 1.12 58.0 ± 5.0 24.0 ± 2.0 34.0 ± 4.0
Tyl et al. 2008cc 19 (F0) 39.53 ± 0.50 72.5 ± 3.6 34.8 ± 2.6 37.7 ± 1.7
16–19 (F1) 38.89 ± 0.53 71.9 ± 2.2 26.5 ± 1.4 45.8 ± 1.7
18 (F1 retained) 40.46 ± 0.67 74.4 ± 2.9 28.8 ± 2.4 45.6 ± 2.2
ND, not determined.
aTen F0 males in control group. bTwenty-five males in control group/generation. cFifty-six males in combined control 
groups/generation.
Table 2. Prostate weights in adult male control mice.
Reference Mouse strain Age (weeks) Whole prostate weight (mg)
Ashby et al. 1999a CF-1 25–26 ~ 50
Cagen et al. 1999a CF-1 13 ~ 40
Gupta 2000 CD-1 8.5–9 ~ 40
Heindel et al. 1995 CD-1 16–17 ~ 45.9
Morrissey et al. 1988 CD-1 23 58.3
Nagel et al. 1997b CF-1 27–28 41
Nonneman et al. 1992b CF-1 14–15 49–59
Ruhlen et al. 2008 CD-1 13  ~ 42
Takahashi and Oishi 2006 CD-1 8.5–9  16–34
vom Saal et al. 1994b CF-1 15  50
vom Saal et al. 1997b CF-1 34–35  42
vom Saal et al. 1994b CF-1 77  105
aCagen et al. (1999) and Ashby et al. (1999) used CF-1 mice purchased from commercial suppliers. bThe closed CF-1 
mouse colony (maintained at the University of Missouri–Columbia since 1979) has since been terminated by vom Saal.Tyl
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to E2 (BPA doses administered were up to 
7,000× higher).
Claim 5. Myers et al. (2009) questioned 
our use of CD-1 Swiss mice from Charles 
River Laboratories (citing strain and source 
differences as the basis for differing results). 
Response. We purchased CD-1 mice from 
Charles River Laboratories (Raleigh, NC) for 
each study. We do not maintain in-house 
colonies because closed colonies (such as the 
CF-1 mouse colony maintained in vom Saal’s 
laboratory since 1979) typically suffer from 
founder effects and/or genetic drift over time; 
vom Saal recently terminated his CF-1 mouse 
colony and began using CD-1 mice. Charles 
River International Gold Standard CD-1 mice 
are maintained by matings across their breed-
ing facilities to preclude/minimize such effects.
Claim 6. Myers et al. (2009) criticized our 
use of gross examinations, organ wet weights, 
tissue histopathology, and systemic and repro-
ductive/developmental landmarks because they 
“were established procedures by the 1950s.”
Response. These parameters have been used 
for many years because they are sensitive, rele-
vant, and validated. Newer end points have 
been added as they are validated (see above).
Claim 7. Our reproductive toxicity study 
did not look at neurobehavioral end points.
Response. Multigeneration studies are not 
designed to investigate neurobehavioral end 
points, although daily clinical observations in 
our studies (Tyl et al. 2002, 2008c) gave no 
indications of neurotoxicity/neurobehavioral 
effects after BPA exposure (e.g., normal mating 
behaviors, nest building, nursing, pup retrieval, 
offspring landmark acquisition). Ema et al. 
(2001) included standard neuro  behavioral 
end points and observed no effects in their 
two-generation, low-dose (0.2–200 µg/kg/day) 
BPA study. Specific U.S. EPA and OECD 
guidelines exist for adult and develop  mental 
neuro  toxicity studies; definitive BPA investi-
gations using these guidelines are planned or 
under way by the FDA and industry.
Claim 8. Myers et al. (2009) said that 
the large number of animals overpowered 
the study and violated National Institutes of 
Health (NIH) and federal guidelines.
Response. Guideline studies are performed 
not just to detect adverse effects but also to 
ascertain dose–response relationships and 
to provide some assurance of safety. These 
studies therefore require different statisti-
cal considera  tions and experimental power. 
OECD and U.S. EPA reproductive toxicity 
guidelines require ≥ 20 pregnant females at 
term per group. Because mice are not typically 
used in guideline-compliant reproductive tox-
icity studies, and we evaluated ordinal (as well 
as continuous) data, we used 28 mice/sex/
group/generation. Studies with small groups 
and group sizes are of limited utility, and 
inappropriate statistical analyses, sometimes 
seen in exploratory studies (e.g., CERHR 
2007), cannot determine whether there are 
treatment-related effects.
Larger numbers of animals per group pro-
vide more statistical power to detect intergroup 
differences. A dose–response trend suggests 
treatment-related effects, whereas no dose–
response trend implies that effects might not 
be treatment related, so studies with only one 
or two dose groups are of limited utility.
Claim 9. Myers et al. (2009) listed BPA 
low-dose effects not present in our GLP 
studies, including altered metabolism (e.g., 
Alonso-Magdalena et al. 2006), adipo  nectin 
secretion (Hugo et al. 2008), epigenetic pro-
gramming causing increased susceptibility to 
prostate cancer (Ho et al. 2006), changed 
gene expression and morphology of mammary 
glands (Durando et al. 2007; Munoz-de-Toro 
et al. 2005; Soto et al. 2008), neuro  anatomic 
(Leranth et al. 2008) and neuro  behavioral 
effects (Ryan and Vandenbergh 2006), 
and altered offspring reproductive systems 
(Markey et al. 2005; Newbold et al. 2007).
Response. Low-dose BPA effects are from 
non  validated end points in explora  tory stud-
ies, most after nonrelevant routes of adminis-
tration: Soto et al. (2008), Markey et al. 
(2005), Munoz-de-Toro (2005), and Durando 
et al. (2007) used subcutaneous osmotic 
mini-pumps; Newbold et al. (2007) and 
Ho (2006) injected BPA; and Leranth et al. 
(2008) implanted sub  cutaneous BPA cap-
sules. Guideline-compliant studies must use 
appropriate routes and validated end points to 
detect adverse outcomes, for example, changes 
in survival, growth and/or develop  ment, body   
and/or organ weights, histo  pathology, and 
systemic and reproductive organ functions. 
Claim 10. Myers et al. (2009) argued that 
“NIH-funded research [is] subject to more 
stringent reviews than GLP.” Their argument 
was that NIH applications require evidence 
of principal investigator competence, state-
of-the-art methods, equipment, laboratory 
environment, publication of their findings in 
peer-reviewed journals, and are challenged by 
independent efforts to replicate their findings. 
Response. Risk-relevant guideline studies 
(including our BPA work) are not explora-
tory or “basic” research studies; they do not 
include unvalidated, cutting-edge techniques 
because they are required to use validated end 
points and parameters; they are welcomed, 
reviewed by experts, and published in highly 
respected journals.
A former Nature editor (Jennings 2006) 
stated that “scientists understand that peer 
review per se provides only a minimal assur-
ance of quality, and that the public conception 
of peer review as a stamp of authentication is 
far from the truth.”
GLP-compliant studies require that all 
participants have current training files; 
have documentation showing that relevant 
SOPs are read, understood, and used; and 
are under independent quality assurance 
oversight. GLPs require that all data be 
included in the study report (and retained). 
Commonly, nega  tive data are not published 
by many explora  tory/basic research studies 
from universities or NGOs because they are 
not considered criti  cal, whereas all data (posi-
tive/negative) are retained in guideline stud-
ies and are important in weight-of-evidence 
evaluations. Our mouse BPA study (Tyl et al. 
2008c) was also under formal oversight by 
noted reproductive toxicolo  gists from the 
United Kingdom, Denmark, Germany, the 
Netherlands, Sweden, and the European 
Chemicals Bureau.
Current publication environments, which 
may distort science, including limited journals 
with high impact, limited journal space, bias 
toward exciting positive studies and certain 
authors, and so forth, concern the National 
Institute of Environmental Health Sciences 
and academia (Young et al. 2008).
There is no guarantee that basic research, 
federally (or other) funded and published in 
peer-reviewed journals, is reproducible or sub-
ject to more stringent review. The following 
are specific examples of non  reproducible data: 
•	Sharpe	et	al.	(1995)	reported	that	gestational	
and lactational exposure of rats to xeno-
estrogens resulted in reduced testicular size 
and sperm production in adult offspring, 
but they rescinded their findings (Sharpe 
et al. 1998) because neither they nor other 
laboratories could replicate their findings. 
•	vom	Saal’s	laboratory	(Nagel	et	al.	1997)	
reported significantly enlarged prostates 
and significantly decreased epididymal 
sperm counts in F1 adult CF-1 offspring 
from maternal BPA oral gavage at 2 and   
20 µg/kg/day on GDs 11–17 (the sperm 
findings were not confirmed at the NTP 
low-dose workshop, held at Research 
Triangle Park, NC, in 2002). Robust 
attempts to replicate vom Saal’s prostate 
findings by Cagen et al. (1999) and Ashby 
et al. (1999) were unsuccessful (discussed 
above). Although not a direct comparison 
with work by Nagel et al. (1997) in CF-1 
mice, Howdeshell et al. (2008) reported 
that EE gavage dosing of Long-Evans rat 
dams at 50 µg/kg/day from GD7 to post-
natal day (PND) 18 reduced offspring body 
and androgen-dependent organ weights. 
However, BPA gavage dosing at 2, 20, or 
200 µg/kg/day from GD7 to PND18 did 
not “signifi  cantly affect any male endpoint, 
including no effects on androgen-dependent 
organ weights or epididymal sperm count” 
(Howdeshell et al. 2008).
•	Hunt	et	al.	(2003)	reported	that BPA from 
cracked polycarbonate caging caused meiotic   
aneuploidy in genetically susceptible female Basic research versus guideline studies on BPA
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mice, and dosing this strain with 20 µg/kg/
day BPA for 7 days caused chromosome 
congression failure (disturbed metaphase 
chromo  some alignment) during oocyte 
meiosis. A repeat of Hunt et al.’s study by 
Eichenlaub-Ritter et al. (2008) found no 
BPA-induced aneuploidy. Pacchierotti et al. 
(2008) found no hyperploidy/polyploidy in 
oocytes/zygotes (but reported increased meta-
phase II oocytes with prematurely separated 
chromatids after chronic BPA exposure).
•	Anway	et	al.	(2005)	reported	that mater-
nal intra  peritoneal injection of vinclozolin 
(100 mg/kg/day) during early gonadal dif-
ferentiation (GDs 8–15) in rats induced 
epigenetic alterations, which caused testicu-
lar histopathology, reduced sperm counts, 
and tumors in four offspring genera  tions. 
Subsequent studies could not replicate 
these findings using intra  peritoneal injec-
tion (Shirai et al. 2006; Strauss et al. 2009) 
or oral dosing (Schneider et al. 2008), and 
Anway et al. (2008) could not reproduce 
their original findings. Gray and Furr (2008) 
gavaged pregnant SD rats with 100 mg/kg/
day vinclozolin on GDs 8–15 or on GDs 
13–17 during androgen-dependent sex dif-
ferentiation (controls dosed on GDs 8–17). 
These authors found no effects on F1 male 
AGD, retained nipples/areolae, hypo  spadias, 
or fertility after GD 8–15 exposure, but 
they did find statistically and biologically 
significant effects on these parameters after 
GD 13–17 exposure, as expected (vinclo-
zolin is an androgen-receptor antagonist). 
Normal testis histo  pathology and epididymal 
sperm counts in F2/F3 generations indicated 
that vinclozolin-related effects (from exposed 
F0 dams) were not transmitted to unexposed 
F2 and F3 offspring (Furr and Gray 2009).
There are also cases of data manipulation/ 
fraud in NIH-supported, peer-reviewed 
research—more than 30 cases documented in 
the past 3 years according to the U.S. Public 
Health Service’s Office of Research Integrity 
(2009). One example is the study of Arnold 
et al. (1996), in which the authors reported 
huge synergistic effects of endocrine disruptors 
in the yeast estrogen assay in vitro. McLachlan 
(1997) rescinded that paper because neither 
his laboratory nor others could replicate the 
findings. It was later determined that there 
was scientific misconduct and the original 
data were fabricated (NIH 2001).
Bell (2008) stated that “a failure in rep-
licability has blighted much of the low-dose 
BPA literature and it is essential to determine 
which, if any, of these findings are capa-
ble of independent replication.” Ioannidis 
(2005) provocatively stated that “most pub-
lished research findings are false,” because the 
smaller studies have less power and therefore 
more bias, so the effects reported are less likely 
to be true.
Claim 11. Myers et al. (2009) stated that 
GLP specifies nothing about the quality of the 
research design, the skills of the technicians, the 
sensitivity of the assays, or whether the methods 
employed are current or out of date. (All of the 
above are central issues in the view of a grant pro-
posal by an NIH panel.)
Response. GLP regulations are the only 
international legal framework that estab-
lishes quality standards and independent   
government-mandated inspections of facili-
ties, study data, and staff training, with severe 
monetary/legal sanctions for noncompliance 
(see, e.g., Office of Research Integrity 2009). 
Many academic institutions are implementing 
GLPs up to full compliance, including qual-
ity assurance oversight. Unlike basic research, 
GLPs require documented owner  ship of data 
(regardless of collection media), verification 
of valid study design, protocol amendments 
for planned changes, protocol deviations for 
unplanned changes, retention of all data, and 
appropriate statistical analyses to ensure con-
fidence in the study design, performance, and 
conclusions, providing assured sensitivity, 
reliability, and validity critical to formal risk 
assessment.
Designs of BPA guideline-compliant, 
reproductive toxicity studies (e.g., Ema et al. 
2001; Tyl et al. 2002, 2008c) and other com-
prehensive studies (e.g., Ashby et al. 1999; 
Cagen et al. 1999; Howdeshell et al. 2008) 
include adverse end points that would result 
from effects, and in some cases include effects 
themselves, reported by the small, exploratory 
research studies. The striking conclusion is that 
none of these guideline-compliant or compre-
hensive studies, regardless of sponsorship, has 
been able to replicate effects reported for low-
dose BPA on prostate or other male/female 
reproductive structures or functions. The novel, 
non  validated end points evaluated by small, 
basic research studies were not evaluated in the 
guideline-compliant studies, but any adverse 
consequences from them, as required for risk 
assessment, were sought and not found.
Weight of Evidence
During weight-of-evidence evaluations, experts 
evaluate relevant articles and reports, with cer-
tain study designs and/or end points assigned 
greater/lesser weight. A number of BPA 
weight-of-evidence assessments (e.g., EFSA 
2006; Goodman et al. 2006, 2008a, 2008b; 
Gray et al. 2004; Willhite et al. 2008) concur 
that studies do not support the hypothesis that 
low-dose oral BPA adversely affects human 
reproductive/develop  mental health.
Conclusions
Ad hominem attacks are not appropriate or 
helpful in discussions of scientific and regu-
latory concerns. This controversy can be 
resolved only if the debate returns to a 
professional level (Sagan 1996). To include 
new end points for hazard/risk assessment, 
we must validate the end points through rig-
orous regulatory acceptance processes, and 
replicate basic study effects using guideline 
studies. Success in validating relevant new end 
points, as well as performance of studies to fol-
low early changes to subsequent adverse con-
sequences in vivo, may provide “phenotypic 
anchoring” needed to use such end points for 
future hazard evaluations and risk assessments.
RefeRences
Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. 
2006. The estrogenic effect of bisphenol A disrupts 
pancrea  tic β-cell function in vivo and induces insulin 
resistance. Environ Health Perspect 114:106–112.
Anway MD, Cupp AS, Uzumcu M, Skinner MK. 2005. Epigenetic 
transgenerational activities of endocrine disruptors and 
male fertility. Science 308:1466–1469.
Anway MD, Rekow SS, Skinner MK. 2008. Comparative anti-
androgenic actions of vinclozolin and flutamide on trans-
generational adult onset disease and spermatogenesis. 
Reprod Toxicol 26(2):100–106.
Arnold SF, Klotz DM, Collins BM, Vonier PM, Gillette LJ Jr, 
McLachlan JA. 1996. Synergistic activation of estrogen 
receptor with combinations of environmental chemicals. 
Science 272(5267):1489–1492.
Ashby J, Tinwell H, Haseman J. 1999. Lack of effects for low 
dose levels of bisphenol A and diethylstilbestrol on the 
prostate gland of CF1 mice exposed in utero. Regul Toxicol 
Pharmacol 30:156–166.
Bartos L, Brain PF. 1993. Physiological responses to social 
status and housing conditions in male mice subject to food 
competition tests. Bull Zool 60:293–296.
Bell DR. 2008. Environmental aneugens—the need for replication 
[Letter]. Trends Genet 25(1):12–13.
Biegel LB, Flaws JA, Hirshfield AN, O’Connor JC, Elliott GS, 
Ladies GS, et al. 1988. Ninety-day feeding and one-
generation reproduction study in Crl:CD BR rats with 
17β-estradiol. Toxicol Sci 44:116–142.
Cagen SZ, Waechter JM, Dimond SS, Breslin WJ, Butala JH, 
Jekat FW, et al. 1999. Normal reproductive organ 
develop  ment in CF-1 mice following prenatal exposure to   
bis  phenol A. Toxicol Sci 50:36–44.
Calafat AM, Weuve J, Ye X, Jia LT, Hu H, Ringer S, et al. 2008. 
Exposure to bisphenol A and other phenols in neonatal 
intensive care unit premature infants. Environ Health 
Perspect 117:639–644; doi:10.1289/ehp.0800265 [Online 
10 December 2008]. 
CERHR  (Center  for  the  Evaluation  of  Risks  to  Human 
Reproduction). 2008. NTP-CERHR Monograph on the 
Potential Human Reproductive and Developmental Effects 
of Bisphenol A. NIH Publication No. 08-5994. Available: 
http://cerhr.niehs.nih.gov/chemicals/bisphenol/bisphenol.
pdf [accessed 17 September 2009].
Chandra M, Frith CH. 1992. Spontaneous neoplasms in aged 
CD-1 mice. Toxicol Lett 61:67–74.
Dekant W, Völkel W. 2008. Human exposure to bisphenol A 
by biomonitoring: methods, results and assessment 
co r r e c t i o n
In Table 1 of the original manuscript pub-
lished online, the age of F1 animals at termi-
nation was given as 16 weeks. The animals 
actually ranged in age from 16 to 19 weeks, 
based on time during the cohabita  tion 
period that mothers were inseminated and 
when pups were delivered [Tyl RW. Ages 
of mice in the two-generation BPA study 
(Letter). Toxicol Sci (in press)]. The table 
has been corrected here. Tyl
1650  v o l u m e  117 | n u m b e r 11 | November 2009  •  Environmental Health Perspectives
of environmental exposures. Toxicol Appl Pharmacol 
228(1):114–134.
Domoradzki JY, Pottenger LH, Thornton CM, Hansen SC, 
Card TL, Markham DA, et al. 2003. Metabolism and 
pharmaco  kinetics of bisphenol A (BPA) and the embryo-
fetal distribution of BPA and BPA-monoglucuronide in CD 
Sprague Dawley rats at three gestational stages. Toxicol 
Sci 26(1):21–34.
Durando M, Kass L, Piva J, Sonnenschein C, Soto AM, Luque EH, 
et al. 2007. Prenatal bisphenol A exposure induces pre-
neoplastic lesions in the mammary gland in Wistar rats. 
Environ Health Perspect 115:80–86.
EFSA (European Food Safety Authority). 2006. Opinion of the 
Scientific Panel on Food Additives, Flavourings, Processing 
Aids and Materials in Contact with Food (AFC) related to 
2,2-bis(4-hydroxyphenyl)propane. EFSA J 428:1–75.
Eichenlaub-Ritter U, Vogt E, Cukurcam S, Sun F, Pacchierotti F, 
Parry J. 2008. Exposure of mouse oocytes to bisphenol A 
causes meiotic arrest but not aneuploidy. Mutat Res 
651(1–2):82–92.
Ema M, Fujii S, Furukawa M, Kiguchi M, Ikka T, Harazono A. 
2001. Rat two-generation reproductive toxicity study of 
bisphenol A. Reprod Toxicol 15:505–523.
FDA (Food and Drug Administration). 1978. Good Laboratory 
Practice Regulations for Nonclinical Laboratory Studies. 
Fed Reg 43(247):60013–60025.
Furr J, Gray LE. 2009. Vinclozolin (V) treatment induces reproduc-
tive malformations and infertility in F1 male rats when admin-
istered during sexual but not gonadal differentiation. The 
effects are not transmitted to the subsequent generations 
[Abstract 1441]. Toxicologist 108(1):298.
Goodman JE, McConnell EE, Sipes IG, Witorsch RJ, Slayton TM, 
Yu CJ. 2006. Updated weight of the evidence evaluation of 
reproductive and developmental effects of low doses of 
bisphenol A. Crit Rev Toxicol 36(5):387–457.
Goodman JE, Witorsch RJ, McConnell EE, Sipes IG, Slayton TM, 
Yu CJ, et al. 2008a. Weight-of-evidence evaluation of 
reproductive and developmental effects of low doses of 
bisphenol A. Critical Rev Toxicol 39(1):1–75.
Goodman JE, Yu CJ, Rhomberg L. 2008b. Bisphenol A: no repro-
ductive or developmental effects at low doses. Risk Sci 
Bull 4:1–11.
Gray GM, Cohen JT, Cunha G, Hughes C, McDonnell EE, 
Rhonberg L, et al. 2004. Weight of the evidence evaluation 
of low-dose reproductive and developmental effects of 
bisphenol A. Hum Ecol Risk Assess 10:879–921.
Gray LE, Furr J. 2008. Vinclozolin induces reproductive mal-
formations and infertility when administered during sexual 
but not gonadal differentiation [abstract 59]. Toxicologist 
102(1):11.
Gupta C. 2000. Reproductive malformation of the male offspring 
following maternal exposure to estrogenic chemicals. 
Proc Soc Exp Biol Med 224:61–68.
Heindel JJ, Chapin RE, George J, Gulati GK, Fail PA, Barnes LH, 
et al. 1995. Assessment of the reproductive toxicity of a 
complex mixture of 25 groundwater contaminants in mice 
and rats. Fundam Appl Toxicol 25(1):9–19.
Ho SM, Tang WY, Belmonte de Freusto J, Prins GS. 2006. 
Developmental exposure to estradiol and bisphenol A 
increases susceptibility to prostate carcinogenesis and 
epigenetically regulates phophodiesterase type 4 variant 4. 
Cancer Res 66(11):5624–5632.
Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC, 
Gray LE Jr. 2008. Gestational and lactational exposure to 
ethinyl estradiol, but not bisphenol A, decreases androgen-
  dependent reproductive organ weights and epididymal 
sperm abundance in the male Long-Evans hooded rat. 
Toxicol Sci 102(2):371–382.
Howdeshell LK, Hotchkiss AK, Thayer KA, Vandenbergh JG, 
vom Saal FS. 1999. Exposure to bisphenol A advances 
puberty. Nature 401:763–764.
Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, 
Ben-Jonathan N. 2008. Bisphenol A at environmentally rele-
vant doses inhibits adiponectin release from human adipose 
tissue explants and adipocytes. Environ Health Perspect 
116:1642–1647; doi:10.1289/ehp.11537 [online 14 August 2008].
Hunt PA, Koehler KE, Susiargo M, Hodges CA, Ilagan I, Voight RC, 
et al. 2003. Bisphenol A exposures causes meiotic aneu-
ploidy in the female mouse. Curr Biol 13:546–553.
Inoue H, Yokota H, Makino T, Yuasa A, Kato S. 2001. Bisphenol A 
glucuronide, a major metabolite in rat bile after liver perfu-
sion. Drug Metab Dispos 29(8):1084–1087.
Inoue H, Yuki G, Yokota H, Kato S. 2003. Bisphenol A glucuronida-
tion and absorption in rat intestine. Biol Reprod 68(3):140–141.
Ioannidis JPA. 2005. Why most published research findings are 
false. PLoS Med 2(8):e124. doi:10.1371/journal.pmed.0020124 
[Online 30 August 2005].
Jennings C. 2006. Quality and value: the true purpose of peer 
review. Nature doi:10.1038/nature05032. Available: http://
www.nature.com/nature/peerreview/debate/nature05032.
html [accessed 18 September 2009].
Kanno J, Onyon L, Peddada S, Ashby J, Jacob E, Owens W. 
2003. The OECD program to validate the rat uterotrophic 
bioassay. Phase 2: dose-response studies. Environ Health 
Perspect 111:1530–1549.
Karbe E. 1987. Granular cell tumors of genital organs, mice. In: 
Monographs on Pathology of Laboratory Animals, Genital 
System (Jones TC, Mohr U, Hunt RD, eds). Berlin:Springer-
Verlag, 282–286.
Latendresse JR, Bucci TJ, Olson G, Mellick P, Weiss C, Thorn B, 
et al. 2009. Genistein and ethinyl estradiol dietary exposures 
in multi  generational and chronic studies induce similar 
polifera  tive lesions in mammary gland of male Sprague-
Dawley rats. Reprod Toxicol doi:10.1016/j.reprotox.2 
009.04.006 [Online 19 April 2009].
Leranth C, Hajszan T, Szigeti-Buck K, Bober J, Maclusky NJ. 
2008. Bisphenol A prevents the synaptogenic response to 
estradiol in hippocampus and prefrontal cortex of ovari-
ectomized nonhuman primates. Proc Natl Acad Sci USA 
105(37):14187–14191.
Markey CM, Wadia PR, Rubin BS, Sonnenschein C, Soto AM. 
2005. Long-term effects of fetal exposure to low doses of 
the xenoestrogen bisphenol A in the female mouse genital 
tract. Biol Reprod 72(6):1344–1351.
Matthews JB, Twomey K, Zacharewski TR. 2001. In vitro and 
in vivo interactions of bisphenol A and its metabolite, 
bisphenol A glucuronide with estrogen receptors α and β. 
Chem Res Toxicol 14:149–157.
McLachlan JA. 1997. Synergistic effect of environmental estro-
gens: report withdrawn. Science 277(5325):462–463.
Morrissey RE, Lamb JC IV, Schwetz BA, Teague JL, Morris RW. 
1988. Association of sperm, vaginal cytology, and repro-
ductive organ weight data with results from continuous 
breeding studies in Swiss (CD-1) mice. Fundam Appl 
Toxicol 11:359–371.
Munoz-de-Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, 
Sonnenschein C, et al. 2005. Perinatal exposure to bisphenol-
A alters peripubertal mammary gland development in mice. 
Endocrinology 146(9):4138–4147.
Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, 
Colborn T, et al. 2008. Why public health agencies cannot 
depend upon Good Laboratory Practices as a criterion for 
selecting data: the case of bisphenol A. Environ Health 
Perspect 117:309–315; doi:10.1289/ehp.0800173 [Online 
23 October 2008].
Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M, 
Welshons WV. 1997. Relative binding affinity-serum modi-
fied access (RBA-SMA) assay predicts the relative in vivo 
bioactivity of the xenoestrogens bisphenol A and octyl-
phenol. Environ Health Perspect 105:70–76.
National Research Council. 2000. Scientific Frontiers in 
Developmental Toxicity and Risk Assessment. Washington, 
DC:National Academy Press. 
Newbold RR, Jefferson WN, Padilla-Banks E. 2007. Long-term 
adverse effects of neonatal exposure to bisphenol A on 
the murine female reproductive tract. Reprod Toxicol 
24(2):253–258.
NIH (National Institutes of Health). 2001. Findings of Scientific 
Misconduct. Notice NOT-OD-02-003. Available: http://
grants.nih.gov/grants/guide/notice-files/NOT-OD-02-003.
html [accessed 22 September 2009].
Nonneman DJ, Ganjam VK, Welshons WV, Vom Saal FS. 1992. 
Intrauterine position effects on steroid metabolism and 
steroid receptors of reproductive organs in male mice. 
Biol Reprod 47(5):723–729.
NTP (National Toxicology Program). 2008. NTP Brief on 
Bisphenol A (CAS No. 80-05-7). Available: http://cerhr.niehs.
nih.gov/chemicals/bisphenol/BPADraftBriefVF_04_14_08.
pdf [accessed 17 September 2009].
OECD. 1998. OECD Series on Principles of Good Laboratory 
Practice and Compliance Monitoring. No. 1 OECD 
Principles of Good Laboratory Practice. Paris:Organisation 
for Economic and Co-operative Development.
OECD  (Organisation  for  Economic  Cooperation  and 
Development). 2001. Guideline for Testing of Chemicals. 
Proposal for Updating Guideline 416, Two-Generation 
Reproduction Toxicity Study. Paris:Organisation for 
Economic Co-operation and Development. Available: 
http://www.oecd.org/dataoecd/18/13/1948466.pdf 
[accessed 17 September 2009].
Office of Research Integrity. 2009. Handling Misconduct – Case 
Summaries Homepage. Available: http://ori.dhhs.gov/mis-
conduct/cases/ [accessed 4 February 2009].
Pacchierotti F, Ranaldi R, Eichenlaub-Ritter U, Attia S, 
Adler ID. 2008. Evaluation of aneugenic effects of bisphe-
nol A in somatic and germ cells of the mouse. Mutat Res 
651(1–2):64–70.
Pottenger LH, Domoradzki JY, Markham DA, Hansen SC, 
Cagen SZ, Waechter JM Jr. 2000. The relative bioavail-
ability and metabolism of bisphenol A in rats is dependent 
upon the route of administration. Toxicol Sci 54:3–18.
Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. 
2001a. Neonatal low- and high-dose exposure to estradiol 
benzoate in the male rat. I. Effects on the prostate gland. 
Biol Reprod 65(5):1496–1505.
Putz O, Schwartz CB, LeBlanc GA, Cooper RL, Prins GS. 2001b. 
Neonatal low- and high-dose exposure to estradiol benzo-
ate in the male rat. II. Effects on male puberty and the 
reproductive tract. Biol Reprod 65(5):1506–1517.
Richter CA, Taylor JA, Ruhlen RR, Welshons WV, vom Saal FS. 
2007. Estradiol and bisphenol A stimulate androgen receptor 
and estrogen receptor gene expression in fetal mouse pros-
tate cells. Environ Health Perspect 115:902–908.
Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, 
Newbold RR, et al. 2008. Low phytoestrogen levels in feed 
increase fetal serum estradiol resulting in the “fetal estro-
genization syndrome” and obesity in CD-1 mice. Environ 
Health Perspect 116:322–328.
Ryan BC, Vandenbergh JG. 2006. Developmental exposure 
to environmental estrogens alters anxiety and spatial 
memory in female mice. Horm Behav 50(1):85–93.
Sagan C. 1996. The fine art of baloney detection. In: The 
Demon-Haunted World: Science as a Candle in the Dark. 
New York:Random House, 201–218.
Schneider S, Kaufmann W, Buesen R, van Ravenzwaay B. 2008. 
Vinclozolin—the lack of a transgenerational effect after 
oral maternal exposure during organogenesis. Reprod 
Toxicol 25(3):352–360.
Sharpe RM, Fisher JS, Millar MM, Jobling S, Sumpter JP. 
1995. Gestational and lactational exposure of rats to xeno-
estrogens results in reduced testicular size and sperm 
production. Environ Health Perspect 103:1136–1143.
Sharpe RM, Turner KJ, Sumpter JP. 1998. Endocrine disruptors 
and testis development [Letter]. Environ Health Perspect 
106:A220–A221.
Shirai T, Takahashi S, Kawabe M, Doi Y, Ogawa K. 2006. Effects 
of anti-androgenic compounds on rat spermatogenesis 
and DNA methylation [Abstract]. Available: http://ecb.jrc.
it/classlab/9402a53_IND_procymidone.doc [accessed 
18 September 2009].
Sinowatz F, Amselgruber W, Plendl J, Neumuller C. 1996. 
Normal development of the testes and male acces-
sory sex organs. In: Pathobiology of the Aging Mouse, 
Vol 1 (Morh U, Dungworth DL, Capen CC, Carlton WW, 
Sundberg JP, Ward JM, eds). Washington, DC:ILSI Press, 
405–420.
Snyder RW, Maness SC, Gaido KW, Welsch F, Sumner SCJ, 
Fennell TR. 2000. Metabolism and disposition of bisphenol A 
in female rats. Toxicol Appl Pharmacol 168:225–234.
Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C. 
2008. Does breast cancer start in the womb? Basic Clin 
Pharmacol Toxicol 102(2):125–133.
Strauss V, Schneider S, Kaufmann W, Ravenzwaay B. 2009. 
Vinclozolin—the lack of a transgenerational effect after 
intraperitoneal maternal exposure during organogenesis 
[Abstract 1456]. Toxicologist 108(1):301.
Sugimura Y, Sakurai M, Hayashi N, Yamashita A, Kawamura J. 
1994. Age-related changes of the prostate gland in the 
senescence-accelerated mouse. Prostate 24:24–32.
Suwa T, Nyska A, Haseman JK, Mahler JF, Maronpot RR. 2002. 
Spontaneous lesions in control B6C3F1 mice and recom-
mended sectioning of male accessory sex organs. Toxicol 
Pathol 30(2):228–234.
Takahashi O, Oishi S. 2006. Male reproductive toxicity of four 
bisphenol antioxidants in mice and rats and their estrogenic 
effect. Arch Toxicol 80(4):225–241.
Thigpen JE, Haseman JK, Saunders HE, Setchell KDR, 
Grant MG, Forsythe DB. 2003. Dietary phytoestrogens 
accelerate the time of vaginal opening in immature CD-1 
mice. Comp Med 53:477–485.
Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, 
vom Saal FS. 2005. Estrogenic chemicals in plastic and oral Basic research versus guideline studies on BPA
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 11 | November 2009  1651
contraceptives disrupt development of the fetal mouse pros-
tate and urethra. Proc Nat Acad Sci USA 102:7014–7019.
Tyl RW, Myers CB, Marr MC, Castillo NP, Seely JC, Sloan CS, et al. 
2006. Three-generation evaluation of dietary para-nonylphe-
nol in CD (Sprague-Dawley) rats. Toxicol Sci 92(1):295–310.
Tyl RW, Myers CB, Marr MC, Castillo NP, Veselica MM, 
Joiner RL, et al. 2008a. One-generation reproductive toxicity 
study of dietary 17β-estradiol (E2; CAS No. 50-28-2) in CD-1 
(Swiss) mice. Reprod Toxicol 25:144–160.
Tyl  RW,  Myers  CB,  Marr  MC,  Sloan  CS,  Castillo  NP, 
Veselica MM, et al. 2008b. Two-generation reproductive 
toxicity evaluation of dietary 17β-estradiol (E2; CAS No. 
50-28-2) in CD-1 (Swiss) mice. Toxicol Sci 102(2):392−412.
Tyl  RW,  Myers  CB,  Marr  MC,  Sloan  CS,  Castillo  NP, 
Veselica MM, et al. 2008c. Two-generation reproductive 
toxicity study of dietary bisphenol A (BPA) in CD-1 (Swiss) 
mice. Toxicol Sci 104(2):362−384.
Tyl RW, Myers CB, Marr MC, Thomas BF, Keimowitz AR, 
Brine AR, et al. 2002. Three-generation reproductive toxicity 
study of dietary bisphenol A (BPA) in CD (Sprague-Dawley) 
rats. Toxicol Sci 68:121–146.
U.S. EPA (U.S. Environmental Protection Agency). 1983. 
Good Laboratory Practice (GLP) Regulations, Federal 
Insecticide Fungicide and Rodenticide Act (FIFRA). Fed 
Reg 48:53946–53969.
U.S. EPA. 1985. Final TSCA GLP Enforcement Response Policy.
Washington, DC:U.S. Environmental Protection Agency. 
Office of Pesticides and Toxic Substances.
U.S. EPA. 1989. Toxic Substances Control Act (TSCA), Good 
Laboratory Practice Standards. Fed Reg 54(158):34034–34050.
U.S. EPA (U.S. Environmental Protection Agency). 1996. Proposed 
Guidelines for Carcinogen Risk Assessment. Available: 
http://www.epa.gov/raf/publications/pdfs/  propcra_  1996.pdf 
[accessed 17 September 2009].
U.S. EPA. 1997. TSCA reproduction and fertility effects. Fed 
Reg 62(158):43834–43838.
U.S. EPA. 1998. Health Effects Test Guidelines, OPPTS 870.3800, 
Reproduction and Fertility Effects (Final Guideline, August 
1998). Washington, DC:Office of Prevention, Pesticides, 
and Toxic Substances.
Völkel W, Colnot T, Csanady GA, Filser JG, Dekant W. 2002. 
Metabolism and kinetics of bisphenol A in humans at low 
doses following oral administration. Chem Res Toxicol 
15:1281–1287.
vom Saal FS, Finch CE, Nelson JF. 1994. Natural history and 
mechanisms of aging in humans, laboratory rodents and 
other selected vertebrates. In: Physiology of Reproduction, 
Vol 2 (Knobil E, Neill J, Pfaff D, eds). New York:Raven 
Press, 1213–1314.
vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, 
Nagel SC, et al. 1997. Prostate enlargement in mice due to 
fetal exposure to low doses of estradiol or diethyl  stil  bestrol 
and opposite effects at high doses. Proc Natl Acad Sci 
USA 94:2056–2061.
Waymouth C, Cornan DR, Ward-Bailey PF. 1983. Spontaneous 
tumors of the prostate gland in inbred strains of mice. 
J Natl Cancer Inst 70:199–208.
Willhite CC, Ball GL, McLellan CJ. 2008. Derivation of a bis-
phenol A oral reference dose (RfD) and drinking water 
equivalent concentration. J Toxicol Environ Health B Crit 
Rev 11:69–146.
Young NS, Ioannidis JPA, Al-Ubaydli O. 2008. Why current 
publication practices may distort science. The market for 
exchange of scientific information: the winner’s curse, arti-
ficial scarcity, and uncertainty in biomedical publication. 
PLoS Med doi:10.1371/journal.pmed.0050201.sd001.